|
|
Strategic Perspectives: Commercial Opportunites in Depression - Generating Revenue Growth In Symptoms And ComorbiditiesPublished by: Datamonitor Published: Jan. 7, 2003 - 148 Pages Table of ContentsCHAPTER 1 EXECUTIVE SUMMARY
1.2 Datamonitor insight into the commercial opportunities available in the depression market Sleep disorders are the most important symptom influencing antidepressant drug choice. The treatment of sleeping disorders offers opportunities for new manufacturers to enter the depression market and potential secondary indications for Organon and Bristol-Myers Squibb Opinion leaders identified physical symptoms of depression as a key area for growth, as it is an underdeveloped market. Datamonitor believes that both Wyeth and Lilly will specifically target these symptoms over the next few years and should consider moving into other pain areas to maximize revenues Movement into anxiety disorders has traditionally been the main line extension strategy for antidepressant medications. However, the competitiveness of this market means that players must seek out under developed areas, such as GAD or SAD, to ensure this strategy provides a solid return on investment Antidepressant manufacturers must target non-anxiety disorders, such as eating disorders, to ensure that growth rates are sustained. However, despite the clear opportunities that exist in these markets, Datamonitor believes that manufacturers will have to develop sophisticated entry strategies to ensure revenue success Conclusion CHAPTER 2 INTRODUCTION
Analysis of depressive symptoms Analysis of comorbid disorders CHAPTER 3 THE PREVALENCE OF DEPRESSIVE SYMPTOMS
Diagnostic criteria of major depressive disorder 3.2 Sleeping problems Existing key player: mirtazapine Datamonitor strategic recommendation New manufacturers must target Remeron 3.3 Anxiety Existing key player: the SSRIs Datamonitor strategic recommendations A key opportunity in anxiety symptoms exists in Japan The barriers to entry in other key pharmaceutical markets are very high 3.4 Poor concentration Existing key player: the SSRIs Datamonitor strategic recommendation Poor concentration has a high patient potential but huge barriers to entry 3.5 Loss of interest Existing key player: citalopram/escitalopram Datamonitor strategic recommendation Lundbeck/Forest should target Lexapro at this area 3.6 Fatigue Existing key player: fluoxetine Datamonitor strategic recommendation Fatigue is a key commercial opportunity for new antidepressant manufacturers 3.7 Depressed mood Existing key player: venlafaxine Datamonitor strategic recommendation Depressed mood should be used as base to move into other areas 3.8 Weight gain Existing key players: bupropion SR/nefazodone Datamonitor strategic recommendations Wellbutrin or Serzone must be used as the comparator drug BMS should try to increase the importance of weight gain with physicians 3.9 Weight loss Existing key player: mirtazapine Datamonitor strategic recommendation Only niche players should target weight loss symptoms 3.10 Irritability/aggression Existing key player: fluoxetine Datamonitor strategic recommendations Prozac is the gold standard, but its position is vulnerable Key manufacturers should investigate combination therapy 3.11 Lack of self-esteem Existing key player: reboxetine Datamonitor’s strategic recommendation Low self-esteem can potentially lengthen treatment regimens An opportunity exists for noradrenergic medications in the US 3.12 Sexual problems Existing key player: bupropion SR Datamonitor strategic recommendations Wellbutrin SR gold standard comparator in US, although Remeron is useful in EUmarkets The targeting of female patients Opportunities for non-antidepressant therapies to reach the depression market 3.13 Constipation Existing key player: fluoxetine Datamonitor’s strategic recommendation Constipation is not a well-defined symptom of depression As the level of TCA use declines, so does drug-induced constipation 3.14 Somatic symptoms Existing key player: duloxetine Datamonitor strategic recommendation Lilly has a strong launch strategy for duloxetine that also outlines its potential to move into other markets 3.15 Suicidal behavior Suicidal thoughts Suicide attempts Suicide: a conclusion A commercial opportunity for non-antidepressant medications? The targeting of venlafaxine CHAPTER 4 THE PREVALENCE OF COMORBID ANXIETY DISORDERS
Chapter overview 4.2 Generalized anxiety disorder Other studies Key current players Commercial opportunities 4.3 Premenstrual dysphoric disorder Key issues with the US PMDD market Commercial opportunity PMDD should not be a front-line strategy-but offers expansion for established players 4.4 Obsessive compulsive disorder Other studies Key current players Commercial opportunity OCD is over-crowded compare to other anxiety disorder markets 4.5 Post traumatic stress disorder Other studies Key current players Commercial opportunities Strategic opportunity hampered by differing awareness levels Individual nature of PTSD within anxiety spectrum offers unique opportunity Conclusion 4.6 Social anxiety disorder Other studies Key current players Commercial opportunities GSK need to produce head-to-head trials for Paxil SAD offers a high ROI to new manufacturers 4.7 Panic disorder Other studies Key current players Commercial opportunity Panic disorder offers commercial opportunities for non-serotonergic medications 4.8 Agoraphobia Other studies Key current players Commercial opportunity Agoraphobia should be a target for niche competitors only 4.9 Specific phobia Other studies Key current players Commercial opportunity Relatively high comorbidity of specific phobia in the US 4.10 Anxiety disorder not otherwise specified Commercial opportunity Anxiety disorder NOS - a challenge to the traditional anxiety strategy followed by antidepressant manufacturers? CHAPTER 5 THE PREVALENCE OF OTHER COMORBID DISORDERS
Chapter overview 5.2 Bulimia nervosa Other studies Strategic and commercial recommendations Misdiagnosis can be beneficial for antidepressant manufacturers Bulimia only offers a niche indication Prozac is the gold standard but leaves a huge unmet need 5.3 Anorexia nervosa Other studies Strategic and commercial recommendations Incomplete epidemiological research raises the barrier to entry Prozac is the current market leader A clear opportunity exists for new manufacturers Binge eating disorder Other studies Strategic and commercial recommendations Despite a higher prevalence, BED remains the most stigmatized eating disorder Traditionally, antidepressant manufacturers have focused on other eating disorders leaving a gap in the market 5.4 Smoking addiction Other studies Strategic and commercial recommendations High comorbidity but little commercial potential Encouraging off-label use will generate highest ROI Manufacturers must emphasize the acute problem of smoking addiction in MDD patients 5.5 Alcohol dependence Other studies Strategic and commercial recommendations Large patient potential with little antidepressant movement Combination therapy is a potential entry strategy 5.6 Substance abuse disorder Other studies Strategic and commercial recommendations SSRIs are first-line therapies although the clinical evidence is poor SSRI manufacturers should instigate combination therapy Other treatment options - venlafaxine? Addictive disorders: a conclusion 5.7 Self-harm disorder Other studies Strategic and commercial recommendations Pharmaceutical companies must lobby healthcare providers to screen for self-harming in depression patients Little evidence of pharmacological efficacy 5.8 Insomnia Other studies Strategic and commercial recommendations An opportunity for a primary indication for existing manufacturers? 5.9 Dementia Other studies Strategic and commercial recommendations The need for a clean drug-drug interaction profile Celexa: laying the groundwork for Lexapro? CHAPTER 6 APPENDIX A: ABOUT THE REPORT
6.2 Table of tables 6.3 Table of figures 6.4 Bibliography 6.5 Websites 6.6 Physician research methodology Introduction Hypothesis formulation Opinion leader research Pilot interviews Physician recruitment Hypothesis testing Validation and quality control Opinion leader research Quality control CHAPTER 7 APPENDIX B: ABOUT DATAMONITOR
About Datamonitor Healthcare Datamonitor Healthcare’s research and analysis methodologies 7.2 Datamonitor Healthcare’s therapy area capabilities About the CNS analysis team Datamonitor Healthcare’s Consulting expertise Datamonitor’s Therapeutic Consulting expertise Key therapy team members Simon Hemsworth, Director of Therapy Area Analysis Dr. Susanne Begley, Head of Central Nervous System Business Unit David Abramson, Therapeutic Lead Consultant Nick Alcock, Managing Analyst, Central Nervous System Disclaimer AbstractIntroduction:The growth of the antidepressant market over the last decade has been built upon increasingly sophisticated marketing strategies. This has not only made the depression market highly competitive, but also produced an expanded patient potential as manufacturers move their products into non-traditional markets. Scope: * Analysis of depressive symptoms in presenting patients from the seven major markets * Analysis of depressive symptoms throughout the course of the illness in treated patients from the seven major markets * The level of comorbidity of anxiety and non-anxiety disorders in treated depression patients from the seven major markets * Analysis of the leading products in each of these areas of the depression market * Datamonitor’s strategic recommendations for marketed and pipeline drugs. Report Highlights: Traditionally, manufacturers have sought indications in anxiety disorders to ensure product growth. However, following the licensing of fluoxetine for bulimia and bupropion for smoking cessation, Datamonitor has identified a third phase of potential development for antidepressant drugs. By targeting non-anxiety disorders, manufacturers are continually escalating the patient potential for their drugs, which is crucial if the rapid expansion of the antidepressant is to be continued in this decade.The understanding of the prevalence level of depressive symptoms, both at presentation and throughout the illness, is key for all antidepressant manufacturers to devise successful marketing strategies. Furthermore, the competitive landscape in these sub-markets is crucial to understand, if a significant return on investment is to be achieved.Reasons to Purchase: * Understand the prevalence level of depressive symptoms in the treated population * Enhance your understanding of how these symptoms respond to current therapies * Identify the prevalence level of specific anxiety disorders in the treated depression population * Increase your understanding of the prevalence level of non-anxiety disorders in depression patients * Discover the commercial and strategic opportunities that exist in these areas of the depression marketGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||